{"schema_version":"secwatch.filing_event.v1","accession":"0001490978-23-000023","form_type":"8-K","ticker":"SDGR","cik":"0001490978","company_name":"Schrodinger, Inc.","filed_at":"2023-02-28T23:59:59+00:00","discovered_at":"2026-05-14T18:03:45.223143+00:00","generated_at":"2026-06-18T21:51:34.866223+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Schrödinger FY2022 total revenue $181M (+31%); Q4 revenue $56.8M (+23%); net loss widens to $149M","bullets":["FY2022 total revenue $181.0M (+31% YoY); software revenue $135.6M (+20%), drug discovery $45.4M (+84%).","Net loss $149.2M versus $101.2M in 2021; operating expenses $247.8M (+40%).","Q4 total revenue $56.8M (+23%); software revenue $47.8M (+24%), drug discovery $9.0M (+19%).","FY2023 guidance: software revenue growth 13-17%, drug discovery revenue $70-90M, cash burn expected to decline.","Received ~$111.3M cash distribution from Nimbus in Feb 2023; expects ~$36M additional in Q2 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001490978-23-000023","json":"https://secwatch.observer/filing/0001490978-23-000023.json","markdown":"https://secwatch.observer/filing/0001490978-23-000023.md","text":"https://secwatch.observer/filing/0001490978-23-000023.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1490978/000149097823000023/0001490978-23-000023-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1490978/000149097823000023/sdgr-20230228.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-18T21:51:34.866223+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"a393458fa4f85f4cbfe1f08683b6c1c9ab60adc9","claim":"Schrodinger, Inc. reported Fiscal year ending December 31, 2023 results: revenue Software revenue growth expected to be in the range of 13 to 17 percent; Drug discovery revenue expected to range from $. Guidance initiated.","evidence_excerpt":"• Software revenue growth is expected to be in the range of 13 to 17 percent • Drug discovery revenue is expected to range from $70 million to","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1490978/000149097823000023/0001490978-23-000023-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"Fiscal year ending December 31, 2023"},{"label":"Revenue","value":"Software revenue growth expected to be in the range of 13 to 17 percent; Drug discovery revenue expected to range from $"},{"label":"Guidance","value":"initiated"},{"label":"Result","value":"guidance update"}],"fact_type":"earnings_release"},{"claim_id":"c0ec110f222660b5e4da2f7df93054e199b1f458","claim":"Schrodinger, Inc. reported Twelve months ended December 31, 2022 results: revenue Total revenue $181.0 million, net income Net loss $(149.2) million.","evidence_excerpt":"Total revenue for the full year increased 31% to $181.0 million, compared to $137.9 million for 2021. • Software revenue for the full year 2022 increased 20% to $135.6 million, compared to $113.2 million for 2021, with multi-year agreements making a similar contribution to reported revenue to the contribution in 2021 and 2020. • Drug discovery revenue for the full year was $45.4 million for the full year 2022, compared to $24.7 million for 2021. • Software gross margin was 78% for the full year, compared to 77% for 2021. • Operating expenses were $247.8 million for the full year, compared to $177.1 million for 2021. • Other expense, which includes gains/loss on equity investments, changes in fair value of such investments and interest income/expense, was $2.3 million for the full year, compared to other income of $10.6 million for 2021. • Net loss for the full year was $149.2 million, compared to $101.2 million for 2021.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1490978/000149097823000023/0001490978-23-000023-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"Twelve months ended December 31, 2022"},{"label":"Revenue","value":"Total revenue $181.0 million"},{"label":"Net income","value":"Net loss $(149.2) million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}